Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. IPH Limited
  6. News
  7. Summary
    IPH   AU000000IPH9

IPH LIMITED

(IPH)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
The feature you requested does not exist. However, we suggest the following feature:

Innate Pharma Molecule Shows Anti-Tumor Effect in Preclinical Studies

06/10/2021 | 04:32am EDT


© MT Newswires 2021
All news about IPH LIMITED
06/10Innate Pharma Molecule Shows Anti-Tumor Effect in Preclinical Studies
MT
02/17IPH  : Intellectual Property Services Provider IPH's Fiscal Half Statutory Net P..
MT
01/20IPH  : Morgans rates IPH as Add
AQ
2020ASTRAZENECA  : Innate Pharma To Return Immunotoxin's Commercialization Rights In..
MT
2020IPH  : Growth Plans Undaunted
AQ
2020IPH  : Morgans rates IPH as Add
AQ
2016IPH (ASX : IPH) discusses Asian expansion strategy
FI
2015IPH  : on track for solid growth
FI
More news
Financials
Sales 2021 361 M 278 M 278 M
Net income 2021 56,0 M 43,2 M 43,2 M
Net Debt 2021 67,7 M 52,1 M 52,1 M
P/E ratio 2021 -
Yield 2021 4,00%
Capitalization 1 527 M 1 175 M 1 177 M
EV / Sales 2021 4,42x
EV / Sales 2022 4,18x
Nbr of Employees 900
Free-Float 97,8%
Chart IPH LIMITED
Duration : Period :
IPH Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPH LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 8,17 AUD
Last Close Price 7,03 AUD
Spread / Highest target 26,6%
Spread / Average Target 16,3%
Spread / Lowest Target 7,40%
EPS Revisions
Managers and Directors
NameTitle
Andrew Nathaniel Blattman Chief Executive Officer, Executive Director & MD
John Wadley Chief Financial Officer
Richard John Grellman Independent Non-Executive Chairman
John Atkin Independent Non-Executive Director
Robin Jane Low Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
IPH LIMITED9.33%1 175
CINTAS CORPORATION-0.18%37 067
TELEPERFORMANCE SE17.51%22 650
EDENRED SE7.46%15 015
BUREAU VERITAS SA20.27%14 228
LG CORP.12.00%13 995